On Jul. 26, 2018, Sumgen completed a 50 million RMB series A funding with CCBT Private Equity Fund (hereinafter “CCBT”). This fund will be mainly used for the R&D of multiple innovative antibody drugs.
Sumgen specializes in the R&D and industrialization of innovative antibody drugs and has established a wholly-owned R&D center in Beijing-Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. Sumgen uses a combination of computer-aided design (CAD) and mammalian cell display technology to screen and optimize antibody drugs, and has several product pipelines in oncology. According to Sumgen’s founder Dr. Lv, the company aims to become a world-leading enterprise that specializes in antibody drug R&D and industrialization with continuous innovation. Mr. Yuan, general manager of CCBT, praised Sumgen for their growth, execution, and extensive experience in R&D. Mr. Yuan is convinced by the advantages in the company’s technology platform and product pipelines, and believes that there is a bright future ahead of Sumgen.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
